Mesoblast Balance Sheet Health
Financial Health criteria checks 4/6
Mesoblast has a total shareholder equity of $508.7M and total debt of $115.8M, which brings its debt-to-equity ratio to 22.8%. Its total assets and total liabilities are $670.3M and $161.6M respectively.
Key information
22.8%
Debt to equity ratio
US$115.76m
Debt
Interest coverage ratio | n/a |
Cash | US$77.55m |
Equity | US$508.73m |
Total liabilities | US$161.55m |
Total assets | US$670.29m |
Recent financial health updates
Recent updates
Mesoblast Limited: Back From The Dead
Apr 10Mesoblast GAAP EPS of -$0.14, revenue of $10.21M
Aug 31Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS
Apr 30Mesoblast issues FQ2 operational and financial update
Jan 29Mesoblast's rexlemestrocel-l reduces heart attacks, strokes
Jan 11Mesoblast: The Future Looks Bleak
Dec 24Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events
Dec 15Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%
Dec 02Mesoblast EPS beats by $0.22, misses on revenue
Nov 19Financial Position Analysis
Short Term Liabilities: MESO's short term assets ($85.2M) exceed its short term liabilities ($31.4M).
Long Term Liabilities: MESO's short term assets ($85.2M) do not cover its long term liabilities ($130.2M).
Debt to Equity History and Analysis
Debt Level: MESO's net debt to equity ratio (7.5%) is considered satisfactory.
Reducing Debt: MESO's debt to equity ratio has increased from 12.1% to 22.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MESO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MESO has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 0.9% each year.